Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHI-101 monotherapy arm for FLT3-mutated acute myeloid leukemia with MRD failure in the AMLM26 INTERCEPT platform
ACTRN12625000824460Phase 2Recruiting
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lasmotinib in acute myeloid leukemia (AML), sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoint: MRD clearance rate. Started Mar 2026; status: recruiting.
02
Drugs
lasmotinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ACTRN12625000824460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000824460.